Motley Fool

Better Buy: Bristol Myers Squibb vs. Merck

Pharmaceutical giant Merck (NYSE: MRK) has recently made headlines with its oral COVID-19 pill that was just approved in the U.K. Its competitor, Bristol Myers Squibb (NYSE: BMY), is looking to start reaping rewards from a late 2020 purchase of heart medication specialist MyoKardia. George Budwell (Bristol Myers Squibb): With its shares trading at less than three times sales over the prior 12-month period, Bristol Myers Squibb is easily one of the cheapest big pharma stocks right now. First off, Bristol didn’t take part in the COVID vaccine bonanza, which has been a key growth driver for several of its peers this year.